<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-5044</journal-id>
<journal-title><![CDATA[Revista mexicana de neurociencia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. neurocienc.]]></abbrev-journal-title>
<issn>1665-5044</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Neurología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-50442020000700001</article-id>
<article-id pub-id-type="doi">10.24875/rmn.m20000077</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Long-term response in clinical practice to the application of botulinum neurotoxin type A in patients with cervical dystonia]]></article-title>
<article-title xml:lang="es"><![CDATA[Respuesta a largo plazo a la aplicación de la neurotoxina botulínica tipo A en pacientes con distonía cervical]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Ruíz]]></surname>
<given-names><![CDATA[Minerva]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quiñones-Aguilar]]></surname>
<given-names><![CDATA[Sandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez Hernández]]></surname>
<given-names><![CDATA[Juan F.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Franco]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Violante]]></surname>
<given-names><![CDATA[Mayela de J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quiñones-Canales]]></surname>
<given-names><![CDATA[Gerardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Espinosa-Sierra]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Mexico City  ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Integral Rehabilitation Center Querétaro CRIQ ]]></institution>
<addr-line><![CDATA[Querétaro ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Neurología y Neurocirugía"Manuel Velasco Suárez"  ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Zambrano Hellion  ]]></institution>
<addr-line><![CDATA[ Nuevo León]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<volume>21</volume>
<fpage>1</fpage>
<lpage>6</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-50442020000700001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-50442020000700001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-50442020000700001&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Cervical dystonia (CD) is the most common form of focal dystonia, in which application of botulinum neurotoxin type A (BoNT-A) is the first-line treatment. However, information related to its long-term effectiveness is sparse. The aim of this study was to evaluate satisfaction and clinical response in patients with CD.  Methods: An international, observational, multicenter, and prospective study was conducted (INTEREST IN CD2) to evaluate the course of patients treated with BoNT-A over 3 years, with intermediate assessments at each injection visit. This is a sub-analysis that considers information from Latin American countries (Mexico and Brazil). Data from patients with CD were collected in an electronic case report form. The main outcomes were satisfaction at the time of the visit, before BoNT-A injection, regarding the control of the symptoms assessed with a Likert scale and the CD features evaluated by Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Descriptive statistics were performed considering the significance of 95%.  Results: Data from 79 patients were analyzed; 84.8% received abobotulinumtoxin A with a mean dose of 599.7 ± 238.05 U; 7.93 ± 3.01 treatment cycles in 7.45 ± 4.25 muscles; and an average BoNT-A application of 120.3 ± 25.5 days. At baseline, 37.2% of patients stated that they were completely satisfied; meanwhile, at the end of the follow-up, the figure was 70.3%, suggesting an improvement on the rate of today's satisfaction of 88.9%. The total baseline TWSTRS score was 40.2 ± 14.1, while at 3 years it was 23.2 ± 11.5, a tendency to decrease this score was observed registering a greater reduction, from &#8722;17.0, after 36 months.  Conclusion: Results of this study suggest an improvement in the proportion of satisfied patients with CD treated with BoNT-A during a 36-month follow-up.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: La distonía cervical (DC) se define como una enfermedad idiopática y la forma más frecuente de distonía focal. La aplicación de neurotoxina botulínica tipo A (BoNT-A) se ha convertido en el tratamiento de primera línea para pacientes con DC. Sin embargo, falta información relacionada con su efectividad a largo plazo. El objetivo de este estudio fue evaluar la satisfacción y la respuesta clínica en pacientes con DC en la práctica clínica.  Métodos: Se realizó un estudio prospectivo internacional, observacional y multicéntrico (INTEREST IN CD2) para evaluar el curso de los pacientes tratados con BoNT-A a tres años de la primera aplicación y con vigilancia cada seis meses. Éste es un subanálisis que considera datos de países de Latinoamérica (México y Brasil). Los datos de pacientes con DC idiopática se recopilaron en un formulario electrónico de informe de caso. Los desenlaces principales fueron la satisfacción del sujeto con respecto al control de los síntomas bajo la consideración de una escala Likert y las características funcionales evaluadas a partir del instrumento TWSTRS. Se realizó estadística descriptiva y se asumió un nivel de significancia del 95%.  Resultados: Se incluyó a 79 pacientes, 84.8% recibieron toxina abobotulínica A con una dosis promedio de 599.7 ± 238.05 unidades; 7.93 ± 3.01 ciclos de aplicación en 7.45 ± 4.25 mñsculos y una media de aplicación de BoNT de 120.3 ± 25.5 días. Al inicio del estudio, el 55.8% declaró estar satisfecho; 37.2% indicó estar completamente satisfecho con aumento hasta de 87% del grado de satisfacción. La puntuación total basal del TWSTRS fue de 40.2 ± 14.1, mientras que a tres años fue de 23.2 ± 11.5; se observó una tendencia a la disminución de este puntaje y se registró una mayor reducción (de 17 puntos a los 36 meses).  Conclusión: Este estudio sugiere que pacientes con DC bajo tratamiento con BoNT muestran una tasa elevada de satisfacción y respuesta clínica, con una mejoría constante durante un seguimiento de 36 meses.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Cervical dystonia]]></kwd>
<kwd lng="en"><![CDATA[Botulinum neurotoxin type A]]></kwd>
<kwd lng="en"><![CDATA[Effectiveness]]></kwd>
<kwd lng="es"><![CDATA[Distonía cervical]]></kwd>
<kwd lng="es"><![CDATA[Neurotoxina botulínica tipo A]]></kwd>
<kwd lng="es"><![CDATA[Efectividad]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steeves]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dykeman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jette]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pringsheim]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prevalence of primary dystonia: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Mov Disord]]></source>
<year>2012</year>
<volume>27</volume>
<page-range>1789-96</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castel&#1075;o]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marques]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sampaio]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Botulinum toxin Type A therapy for cervical dystonia]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2017</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colosimo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Charles]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Misra]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Maisonobe]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Om]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<collab>INTEREST IN CD2 study group</collab>
<article-title xml:lang=""><![CDATA[How satisfied are cervical dystonia patients after 3 years of botulinum toxin Type A treatment?Results from a prospective, long-term observational study]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2019</year>
<volume>266</volume>
<page-range>3038-46</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Safarpour]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Jabbari]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Botulinum toxin treatment of movement disorders]]></article-title>
<source><![CDATA[Curr Treat Options Neurol]]></source>
<year>2018</year>
<volume>20</volume>
<page-range>4</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramirez-Castaneda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jankovic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term efficacy and safety of botulinum toxin injections in dystonia]]></article-title>
<source><![CDATA[Toxins (Basel)]]></source>
<year>2013</year>
<volume>5</volume>
<page-range>249-66</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colosimo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Misra]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Charles]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Om]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maisonobe]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Poster 187 is there a correlation between tremor and other symptoms of cervical dystonia? An analysis of data from the ongoing INTEREST IN CD2 study]]></article-title>
<source><![CDATA[PM R]]></source>
<year>2016</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Misra]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Colosimo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Charles]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Maisonobe]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Om]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2018</year>
<volume>265</volume>
<page-range>402-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Consky]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical assessments of patients with cervical dystonia]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Jankovic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hallett]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Therapy with Botulinum Toxin]]></source>
<year>1994</year>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Marcel Dekker]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sethi]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Olayinka]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Satisfaction with botulinum toxin treatment:a cross-sectional survey of patients with cervical dystonia]]></article-title>
<source><![CDATA[J Med Econ]]></source>
<year>2012</year>
<volume>15</volume>
<page-range>419-23</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turner-Stokes]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fheodoroff]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jacinto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Maisonobe]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Results from the Upper Limb International Spasticity Study-II (ULISII): a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2013</year>
<volume>3</volume>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nijmeijer]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[de Bruijn]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Verhagen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Forbes]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Kamphuis]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Happee]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spectral EMG changes in cervical dystonia patients and the influence of botulinum toxin treatment]]></article-title>
<source><![CDATA[Toxins (Basel)]]></source>
<year>2017</year>
<volume>9</volume>
<page-range>256</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hefter]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspects of the complexity of cervical dystonia]]></article-title>
<source><![CDATA[Nervenarzt]]></source>
<year>2008</year>
<volume>79</volume>
<numero>Suppl1</numero>
<issue>Suppl1</issue>
<page-range>15-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dressler]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Paus]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Seitzinger]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gebhardt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kupsch]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2013</year>
<volume>84</volume>
<page-range>1014-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jost]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Hefter]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Stenner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Reichel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy]]></article-title>
<source><![CDATA[J Neural Transm (Vienna)]]></source>
<year>2013</year>
<volume>120</volume>
<page-range>487-96</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dressler]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kupsch]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Seitzinger]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Paus]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia]]></article-title>
<source><![CDATA[Eur J Neurol]]></source>
<year>2014</year>
<volume>21</volume>
<page-range>459-62</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Albanese]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sorbo]]></surname>
<given-names><![CDATA[FD]]></given-names>
</name>
<name>
<surname><![CDATA[Comella]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jinnah]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Mink]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Post]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dystonia rating scales:critique and recommendations]]></article-title>
<source><![CDATA[Mov Disord]]></source>
<year>2013</year>
<volume>28</volume>
<page-range>874-83</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
